InvestSMART

BLS Pharmaceuticals Limited (ASX:BLS)

ALERT: Price-sensitive ASX Announcement for BLS
Current share price for BLS : $0.900 0.12 (15.38%)+
Announcement
Release
30 Jul 2026 8:57AM
Price at Release
$0.780
Full Release
download
Summary
BLS Pharmaceuticals Limited, through its subsidiary Breathe Life Sciences, is a globally recognized GMP-licensed manufacturer engaged in the production, import, export, and distribution of regulated therapeutic products, including medicinal cannabis, psilocybin, and MDMA. In FY2026, the company reported record revenues of $75 million, supported by a significant inventory investment and robust cash flow. BLS is strategically expanding its integrated pharmaceutical manufacturing platform across Australia, the UK, and Europe, aiming to meet the growing demand for regulated therapeutics. The company maintains strong international partnerships and supply agreements, including significant expansions in the UK and Germany, and has entered the LATAM market. BLS is also involved in developing advanced drug delivery systems and expanding its product portfolio to include ibogaine and peptides. The leadership team, led by CEO Samuel Watson, emphasizes strategic growth and maintaining competitive advantages through a multi-jurisdictional license stack and GMP expertise.
Key Points
  • Record FY2026 revenue of $75 million.
  • Strong cash flow with $6.3 million in Q4 FY2026.
  • Strategic expansion in the UK, Europe, and LATAM.
  • GMP-certified manufacturing for cannabis, psilocybin, and MDMA.
  • Advanced drug delivery and expansion into ibogaine and peptides.
  • Robust international partnerships and supply agreements.
  • Leadership led by CEO Samuel Watson with strategic growth focus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.